Drug Profile
Amitriptyline/oxymetazoline/ketoprofen - Omeros Corporation
Alternative Names: Ketoprofen/amitriptyline/oxymetazoline; Ketoprofen/oxymetazoline/amitriptyline; OMS 103; OMS-103-HP; Oxymetazoline/amitriptyline/ketoprofenLatest Information Update: 27 Aug 2019
Price :
$50
*
At a glance
- Originator Omeros Corporation
- Class Dibenzocycloheptenes; Imidazoles; Nonsteroidal anti-inflammatories; Phenylpropionates; Small molecules
- Mechanism of Action Alpha 1 adrenergic receptor agonists; Alpha 2 adrenergic receptor agonists; Lipoxygenase-cyclooxygenase inhibitors; Serotonin uptake inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Postoperative pain
Most Recent Events
- 29 Apr 2019 Omeros Corporation has patent protection for amitriptyline/oxymetazoline/ketoprofen in USA and other undisclosed countries
- 29 Apr 2019 Omeros Corporation has patents pending for amitriptyline/oxymetazoline/ketoprofen in USA and other undisclosed countries
- 08 Nov 2018 Chemical structure information added